The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback